AI pioneer Ray Kurzweil signs on with startup seeking to merge minds with machines through nasal spray
Ray Kurzweil has joined Subsense, a Palo Alto startup working on a brain-computer interface that would deliver nanoparticles through the nose. The approach aims to avoid surgery, unlike Neuralink's implants. Subsense has raised $27 million and is in pre-clinical testing, with Kurzweil serving as an advisor.
Subsense, founded four years ago, has secured $27 million in venture funding and remains in pre-clinical development. Its experiments currently involve mice, with human trials not yet underway. The company's proposed delivery method uses charged nanoparticles administered intranasally, which would then be manipulated externally via a headset equipped with magnetic coils to either stimulate or read neural activity.
Kurzweil's advisory role focuses on technology roadmap and the broader trajectory of AI-neural convergence. His involvement lends credibility to Subsense's ambition to eventually transition from medical applications to consumer products. The company's approach contrasts sharply with Neuralink's surgical implants, which have already been placed in roughly a dozen human patients, highlighting the divergent strategies emerging within the brain-computer interface field.
This technology could eventually offer non-surgical alternatives for patients with paralysis or neurological conditions, potentially expanding access beyond those eligible for invasive implants. However, if consumer brain interfaces become reality, they may raise significant concerns about cognitive privacy, data security, and the societal divide between those who can augment their mental capabilities and those who cannot. The merging of human thought with AI systems could fundamentally alter personal autonomy and the nature of human decision-making, warranting careful consideration as development progresses.